{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Among 4 cetuximab non-responders, none had locoregional failure at 2 years. Two patients had known HPV status; one patient was HPV+ and another patient HPV-. HPV status for the other two was unknown. HPV positive patient had no sign of progression within 2 years of follow-up. HPV negative patient had no sign of progression for 210 days until the last follow-up. One HPV unknown patient did not show progression within 2 years of follow-up, and the other HPV unknown patient had no progression for 115 days until the last follow-up.","groups":[{"description":"Patients receive cetuximab IV over 60-120 minutes for 3 weeks. Patients then undergo EBRT over 6-7 weeks. Patients achieving response continue weekly doses of cetuximab until radiation therapy is completed. Patients unable to achieve response or progression receive cisplatin IV over 1-2 hours on days 1, 22, and 43 of radiation therapy.\n\ncetuximab: Given IV\n\ncisplatin: Given IV\n\nexternal beam radiation therapy: Undergo EBRT\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Cetuximab, Cisplatin, EBRT)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"This measure what not evaluated because the study was halted prematurely due to low accrual.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Locoregional Control for Non-responders to Neoadjuvant Cetuximab","type":"SECONDARY","unitOfMeasure":"Participants"}